Compare TASK & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TASK | MYGN |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.9M | 444.2M |
| IPO Year | 2021 | 1996 |
| Metric | TASK | MYGN |
|---|---|---|
| Price | $5.50 | $4.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $14.70 | $7.64 |
| AVG Volume (30 Days) | 476.9K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $5.95 | $6.86 |
| Revenue Next Year | $6.46 | $5.45 |
| P/E Ratio | $21.42 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $5.37 | $3.53 |
| 52 Week High | $18.39 | $8.59 |
| Indicator | TASK | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 49.15 |
| Support Level | $5.39 | $3.53 |
| Resistance Level | $6.62 | $5.30 |
| Average True Range (ATR) | 0.25 | 0.32 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 12.00 | 52.11 |
TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.